Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis

The Lancet Infectious Diseases

Volumn 17, Issue 7, 2017, Pages e223-e234

  Heath, Paul T ^a   Culley, Fiona J ^b   Jones, Christine E ^c   Kampmann, Beate ^d,e   Le Doare, Kirsty ^a,d   Nunes, Marta C ^f   Sadarangani, Manish ^g,h   Chaudhry, Zain ^b   Baker, Carol J ⁱ   Openshaw, Peter J M ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE;

BREAST MILK; COST EFFECTIVENESS ANALYSIS; DISEASE BURDEN; DISEASE SEVERITY; FEMALE; GROUP B STREPTOCOCCAL INFECTION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOBIOLOGY; PLACENTAL TRANSFER; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; STREPTOCOCCUS AGALACTIAE; VACCINATION; DRUG EFFECTS; IMMUNIZATION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PASSIVE IMMUNIZATION; PREGNANCY; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STREPTOCOCCAL INFECTIONS; UTILIZATION;

FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION; INFANT; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 85018554407     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30232-3     Document Type: Review

References (172)

1. Marchant, A, Sadarangani, M, Garand, M, et al. Maternal immunisation: a worldwide landscape analysis. Lancet Infect Dis, 2017 published online April 19 http://dx.doi.org/10.1016/S1473-3099(17)30229-3.
2. Thwaites, CL, Beeching, NJ, Newton, CR, Maternal and neonatal tetanus. Lancet 385 (2015), 362–370.
3. Madhi, SA, Cutland, CL, Kuwanda, L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371 (2014), 918–931.
4. Amirthalingam, G, Andrews, N, Campbell, H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384 (2014), 1521–1528.
5. Abu Raya, B, Edwards, KM, Scheifele, DW, Halperin, SA, Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis, 2017 published online April 19 http://dx.doi.org/10.1016/S1473-3099(17)30190-1.
6. Phares, CR, Lynfield, R, Farley, MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 299 (2008), 2056–2065.
7. Jones, N, Oliver, K, Jones, Y, Haines, A, Crook, D, Carriage of group B streptococcus in pregnant women from Oxford, UK. J Clin Pathol 59 (2006), 363–366.
8. Bergeron, MG, Ke, D, Menard, C, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 343 (2000), 175–179.
9. Heath, PT, Balfour, GF, Tighe, H, et al. Group B streptococcal disease in infants: a case control study. Arch Dis Child 94 (2009), 674–680.
10. Heath, PT, Balfour, G, Weisner, AM, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363 (2004), 292–294.
11. Cutland, CL, Schrag, SJ, Thigpen, MC, et al. Increased risk for group B streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004–2008. Emerg Infect Dis 21 (2015), 638–645.
12. Gray, KJ, Kafulafula, G, Matemba, M, Kamdolozi, M, Membe, G, French, N, Group B streptococcus and HIV infection in pregnant women, Malawi, 2008–2010. Emerg Infect Dis 17 (2011), 1932–1935.
13. Schrag, SJ, Zywicki, S, Farley, MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342 (2000), 15–20.
14. Bekker, V, Bijlsma, MW, van de Beek, D, Kuijpers, TW, van der Ende, A, Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis 14 (2014), 1083–1089.
15. O'Sullivan, C, Lamagni, T, Efstratiou, A, et al. Group B streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014–2015. Arch Dis Child, 101(suppl 1), 2016, A2.
16. Gray, KJ, Bennett, SL, French, N, Phiri, AJ, Graham, SM, Invasive group B streptococcal infection in infants, Malawi. Emerg Infect Dis 13 (2007), 223–229.
17. Madhi, SA, Radebe, K, Crewe-Brown, H, et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 23 (2003), 15–23.
18. Dagnew, AF, Cunnington, MC, Dube, Q, et al. Variation in reported neonatal group B streptococcal disease incidence in developing countries. Clin Infect Dis 55 (2012), 91–102.
19. Edmond, KM, Kortsalioudaki, C, Scott, S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379 (2012), 547–556.
20. Libster, R, Edwards, KM, Levent, F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 130 (2012), e8–15.
21. Bedford, H, de Louvois, J, Halket, S, Peckham, C, Hurley, R, Harvey, D, Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 323 (2001), 533–536.
22. Seale, AC, Blencowe, H, Zaidi, A, et al. Neonatal severe bacterial infection impairment estimates in South Asia, sub-Saharan Africa, and Latin America for 2010. Pediatr Res 74:suppl 1 (2013), 73–85.
23. Nan, C, Dangor, Z, Cutland, CL, Edwards, MS, Madhi, SA, Cunnington, MC, Maternal group B streptococcus-related stillbirth: a systematic review. BJOG 122 (2015), 1437–1445.
24. Randis, TM, Gelber, SE, Hooven, TA, et al. Group B streptococcus beta-hemolysin/cytolysin breaches maternal-fetal barriers to cause preterm birth and intrauterine fetal demise in vivo. J Infect Dis 210 (2014), 265–273.
25. Surve, MV, Anil, A, Kamath, KG, et al. Membrane vesicles of group B streptococcus disrupt feto-maternal barrier leading to preterm birth. PLoS Pathog, 12, 2016, e1005816.
26. Vornhagen, J, Quach, P, Boldenow, E, et al. Bacterial hyaluronidase promotes ascending GBS infection and preterm birth. MBio 7 (2016), e00781–e00816.
27. Whidbey, C, Harrell, MI, Burnside, K, et al. A hemolytic pigment of group B streptococcus allows bacterial penetration of human placenta. J Exp Med 210 (2013), 1265–1281.
28. Valkenburg-van den Berg, AW, Sprij, AJ, Dekker, FW, Dorr, PJ, Kanhai, HH, Association between colonization with group B streptococcus and preterm delivery: a systematic review. Acta Obstet Gynecol Scand 88 (2009), 958–967.
29. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recomm Rep 45 (1996), 1–24.
30. Vergnano, S, Embleton, N, Collinson, A, Menson, E, Russell, AB, Heath, P, Missed opportunities for preventing group B streptococcus infection. Arch Dis Child Fetal Neonatal Ed 95 (2010), F72–F73.
31. Schrag, SJ, Zell, ER, Lynfield, R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 347 (2002), 233–239.
32. Stoll, BJ, Hansen, NI, Sanchez, PJ, et al. Early onset neonatal sepsis: the burden of group B streptococcal and E coli disease continues. Pediatrics 127 (2011), 817–826.
33. Jordan, HT, Farley, MM, Craig, A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 27 (2008), 1057–1064.
34. Weisner, AM, Johnson, AP, Lamagni, TL, et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 38 (2004), 1203–1208.
35. Ferrieri, P, Lynfield, R, Creti, R, Flores, AE, Serotype IV and invasive group B streptococcus disease in neonates, Minnesota, USA, 2000–2010. Emerg Infect Dis 19 (2013), 551–558.
36. Larsson, C, Stalhammar-Carlemalm, M, Lindahl, G, Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine 17 (1999), 454–458.
37. Margarit, I, Rinaudo, CD, Galeotti, CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199 (2009), 108–115.
38. Jones, N, Bohnsack, JF, Takahashi, S, et al. Multilocus sequence typing system for group B streptococcus. J Clin Microbiol 41 (2003), 2530–2536.
39. Meissner, HC, Viral bronchiolitis in children. N Engl J Med 374 (2016), 62–72.
40. Lambert, L, Sagfors, AM, Openshaw, PJ, Culley, FJ, Immunity to RSV in early-life. Front Immunol, 5, 2014, 466.
41. Blanken, MO, Rovers, MM, Molenaar, JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 368 (2013), 1791–1799.
42. Feldman, AS, He, Y, Moore, ML, Hershenson, MB, Hartert, TV, Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med 191 (2015), 34–44.
43. Nair, H, Nokes, DJ, Gessner, BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375 (2010), 1545–1555.
44. Weber, MW, Mulholland, EK, Greenwood, BM, Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 3 (1998), 268–280.
45. Hall, CB, Weinberg, GA, Iwane, MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 (2009), 588–598.
46. Piedra, PA, Jewell, AM, Cron, SG, Atmar, RL, Glezen, WP, Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21 (2003), 3479–3482.
47. Glezen, WP, Paredes, A, Allison, JE, Taber, LH, Frank, AL, Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 98 (1981), 708–715.
48. Parrott, RH, Kim, HW, Arrobio, JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 98 (1973), 289–300.
49. Nolan, T, Borja-Tabora, C, Lopez, P, et al. Prevalence and incidence of respiratory syncytial virus and other respiratory viral infections in children aged 6 months to 10 years with influenza-like illness enrolled in a randomized trial. Clin Infect Dis 60 (2015), e80–e89.
50. Houben, ML, Bont, L, Wilbrink, B, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 127 (2011), 35–41.
51. Simoes, EA, Mutyara, K, Soh, S, Agustian, D, Hibberd, ML, Kartasasmita, CB, The epidemiology of respiratory syncytial virus lower respiratory tract infections in children less than 5 years of age in Indonesia. Pediatr Infect Dis J 30 (2011), 778–784.
52. McLellan, JS, Ray, WC, Peeples, ME, Structure and function of RSV surface glycoproteins. Curr Top Microbiol Immunol 372 (2013), 83–104.
53. McLellan, JS, Chen, M, Leung, S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340 (2013), 1113–1117.
54. Baker, CJ, Kasper, DL, Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294 (1976), 753–756.
55. Dangor, Z, Kwatra, G, Izu, A, Lala, SG, Madhi, SA, Review on the association of group B streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines 14 (2015), 135–149.
56. Baker, CJ, Carey, VJ, Rench, MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 209 (2014), 781–788.
57. Lin, FY, Philips, JB 3rd, Azimi, PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 184 (2001), 1022–1108.
58. Lin, FYC, Weisman, LE, Azimi, PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 190 (2004), 928–934.
59. Kasper, DL, Wessels, MR, Guttormsen, HK, Paoletti, LC, Edwards, MS, Baker, CJ, Measurement of human antibodies to type III group B streptococcus. Infect Immun 67 (1999), 4303–4305.
60. Beachler, CW, Baker, CJ, Kasper, DL, Fleming, DK, Webb, BJ, Yow, MD, Group B streptococcal colonization and antibody status in lower socioeconomic parturient women. Am J Obstet Gynecol 133 (1979), 171–173.
61. Kwatra, G, Adrian, PV, Shiri, T, Buchmann, EJ, Cutland, CL, Madhi, SA, Natural acquired humoral immunity against serotype-specific group B streptococcus rectovaginal colonization acquisition in pregnant women. Clin Microbiol Infect 21 (2015), e13–e21.
62. Brigtsen, AK, Kasper, DL, Baker, CJ, Jennings, HJ, Guttormsen, HK, Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 185 (2002), 1277–1284.
63. Edwards, MS, Lane, HJ, Hillier, SL, Rench, MA, Baker, CJ, Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 30 (2012), 4123–4126.
64. Habibi, MS, Jozwik, A, Makris, S, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 191 (2015), 1040–1049.
65. Roca, A, Abacassamo, F, Loscertales, MP, et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J Med Virol 67 (2002), 616–623.
66. Ogilvie, MM, Vathenen, AS, Radford, M, Codd, J, Key, S, Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 7 (1981), 263–271.
67. Eick, A, Karron, R, Shaw, J, et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J 27 (2008), 207–212.
68. Ochola, R, Sande, C, Fegan, G, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One, 4, 2009, e8088.
69. Freitas, GR, Silva, DA, Yokosawa, J, et al. Antibody response and avidity of respiratory syncytial virus-specific total IgG, IgG1, and IgG3 in young children. J Med Virol 83 (2011), 1826–1833.
70. Stensballe, LG, Ravn, H, Kristensen, K, Meakins, T, Aaby, P, Simoes, EA, Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 154 (2009), 296–298.
71. Le Saux, N, Gaboury, I, MacDonald, N, Maternal respiratory syncytial virus antibody titers: season and children matter. Pediatr Infect Dis J 22 (2003), 563–564.
72. Chu, HY, Steinhoff, MC, Magaret, A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 210 (2014), 1582–1589.
73. Stensballe, LG, Ravn, H, Kristensen, K, et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J Allergy Clin Immunol 123 (2009), 398–403.
74. Kwon, YM, Hwang, HS, Lee, JS, et al. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 104 (2014), 1–6.
75. Buraphacheep, W, Sullender, WM, The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infections in infancy. J Infect Dis 175 (1997), 935–938.
76. Peri, BA, Theodore, CM, Losonsky, GA, Fishaut, JM, Rothberg, RM, Ogra, PL, Antibody content of rabbit milk and serum following inhalation or ingestion of respiratory syncytial virus and bovine serum albumin. Clin Exp Immunol 48 (1982), 91–101.
77. Suffin, SC, Prince, GA, Muck, KB, Porter, DD, Immunoprophylaxis of respiratory syncytial virus infection in the infant ferret. J Immunol 123 (1979), 10–14.
78. Wong, DT, Ogra, PL, Neonatal respiratory syncytial virus infection: role of transplacentally and breast milk-acquired antibodies. J Virol 57 (1986), 1203–1206.
79. Prince, GA, Horswood, RL, Camargo, E, Koenig, D, Chanock, RM, Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 42 (1983), 81–87.
80. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102 (1998), 531–537.
81. Blanken, MO, Rovers, MM, Bont, L, Respiratory syncytial virus and recurrent wheeze. N Engl J Med 369 (2013), 782–783.
82. O'Brien, KL, Chandran, A, Weatherholtz, R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 15 (2015), 1398–1408.
83. Nyiro, JU, Sande, C, Mutunga, M, et al. Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya. Vaccine 33 (2015), 1797–1801.
84. Dunn, SR, Ryder, AB, Tollefson, SJ, Xu, M, Saville, BR, Williams, JV, Seroepidemiologies of human metapneumovirus and respiratory syncytial virus in young children, determined with a new recombinant fusion protein enzyme-linked immunosorbent assay. Clin Vaccine Immunol 20 (2013), 1654–1656.
85. Cox, MJ, Azevedo, RS, Cane, PA, Massad, E, Medley, GF, Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, Brazil. J Med Virol 55 (1998), 234–239.
86. Brandenburg, AH, Groen, J, van Steensel-Moll, HA, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: Limited serological response upon infection. J Med Virol 52 (1997), 97–104.
87. Vieira, SE, Gilio, AE, Durigon, EL, Ejzenberg, B, Lower respiratory tract infection caused by respiratory syncytial virus in infants: the role played by specific antibodies. Clinics (Sao Paulo) 62 (2007), 709–716.
88. McGill, A, Greensill, J, Craft, AW, Fenwick, F, Toms, GL, Measurement of antibody against contemporary virus lineages of human respiratory syncytial virus sub-group A in infants and their mothers. J Clin Virol 30 (2004), 73–80.
89. Kasel, JA, Walsh, EE, Frank, AL, Baxter, BD, Taber, LH, Glezen, WP, Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol 1 (1987), 199–205.
90. Vissers, M, Ahout, IM, de Jonge, MI, Ferwerda, G, Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels. Clin Vaccine Immunol 23 (2016), 243–245.
91. Dhariwal, J, Kitson, J, Jones, RE, et al. Nasal lipopolysaccharide challenge and cytokine measurement reflects innate mucosal immune responsiveness. PLoS One, 10, 2015, e0135363.
92. Jans, J, Vissers, M, Heldens, JG, de Jonge, MI, Levy, O, Ferwerda, G, Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity. Rev Med Virol 24 (2014), 55–70.
93. Jozwik, A, Habibi, MS, Paras, A, et al. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun, 6, 2015, 10224.
94. Openshaw, PJ, Chiu, C, Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 3 (2013), 468–474.
95. Openshaw, P, Edwards, S, Helms, P, Changes in rib cage geometry during childhood. Thorax 39 (1984), 624–627.
96. Culley, FJ, Pollott, J, Openshaw, PJ, Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 196 (2002), 1381–1386.
97. Okoko, JB, Wesumperuma, HL, Hart, CA, The influence of prematurity and low birthweight on transplacental antibody transfer in a rural west African population. Trop Med Int Health 6 (2001), 529–534.
98. van den Berg, JP, Westerbeek, EA, Berbers, GA, van Gageldonk, PG, van der Klis, FR, van Elburg, RM, Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, Haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 29 (2010), 801–805.
99. de Sierra, TM, Kumar, ML, Wasser, TE, Murphy, BR, Subbarao, EK, Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 122 (1993), 787–791.
100. Wilczynski, J, Lukasik, B, Transplacental transfer of antibodies to some respiratory viruses. Acta Microbiol Pol 43 (1994), 347–358.
101. Griffiths, PD, Berney, SI, Argent, S, Heath, RB, Antibody against viruses in maternal and cord sera: specific antibody is concentrated on the fetal side of the circulation. J Hyg 89 (1982), 303–310.
102. Heijtink, RA, Backx, G, Van Der Horst, JM, Masurel, N, Complement fixation and neutralization RS antibodies in maternal and neonatal sera. J Hyg 78 (1977), 411–417.
103. Crowe, JE Jr, Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 33 (2001), 1720–1727.
104. Okoko, BJ, Wesumperuma, LH, Ota, MO, et al. The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural west African population. J Infect Dis 184 (2001), 627–632.
105. Le Doare, K, Allen, L, Kampmann, B, et al. Anti-group B streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine 33 (2015), 621–627.
106. Dangor, Z, Kwatra, G, Izu, A, et al. HIV-1 is associated with lower group B streptococcus capsular and surface-protein IgG antibody levels and reduced transplacental antibody transfer in pregnant women. J Infect Dis 212 (2015), 453–462.
107. Heiman, HS, Weisman, LE, Transplacental or enteral transfer of maternal immunization-induced antibody protects suckling rats from type III group B streptococcal infection. Pediatr Res 26 (1989), 629–632.
108. Edwards, MS, Munoz, FM, Baker, CJ, Antibodies to type III group B streptococcal polysaccharide in breast milk. Pediatr Infect Dis 23 (2004), 961–963.
109. Holberg, CJ, Wright, AL, Martinez, FD, Ray, CG, Taussig, LM, Lebowitz, MD, Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 133 (1991), 1135–1151.
110. Sommer, C, Resch, B, Simoes, EA, Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 5 (2011), 144–154.
111. Bulkow, LR, Singleton, RJ, Karron, RA, Harrison, LH, Alaska, RSVSG, Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 109 (2002), 210–216.
112. Dixon, DL, Griggs, KM, Forsyth, KD, Bersten, AD, Lower interleukin-8 levels in airway aspirates from breastfed infants with acute bronchiolitis. Pediatr Allergy Immunol 21 (2010), e691–e696.
113. Tsutsumi, H, Honjo, T, Nagai, K, Chiba, Y, Chiba, S, Tsugawa, S, Immunoglobulin A antibody response to respiratory syncytial virus structural proteins in colostrum and milk. J Clin Microbiol 27 (1989), 1949–1951.
114. Nandapalan, N, Taylor, C, Scott, R, Toms, GL, Mammary immunity in mothers of infants with respiratory syncytial virus infection. J Med Virol 22 (1987), 277–287.
115. Toms, GL, Gardner, PS, Pullan, CR, Scott, M, Taylor, C, Secretion of respiratory syncytial virus inhibitors and antibody in human milk throughout lactation. J Med Virol 5 (1980), 351–360.
116. Fishaut, M, Murphy, D, Neifert, M, McIntosh, K, Ogra, PL, Bronchomammary axis in the immune response to respiratory syncytial virus. J Pediatr 99 (1981), 186–191.
117. Ogra, PL, Losonsky, GA, Fishaut, M, Colostrum-derived immunity and maternal-neonatal interaction. Ann N Y Acad Sci 409 (1983), 82–95.
118. Nandapalan, N, Taylor, CE, Greenwell, J, et al. Seasonal variations in maternal serum and mammary immunity to RS virus. J Med Virol 20 (1986), 79–87.
119. Lancefield, RC, A serological differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med 59 (1934), 441–458.
120. Baker, CJ, Paoletti, LC, Wessels, MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 179 (1999), 142–150.
121. Anderson, DC, Hughes, BJ, Edwards, MS, Buffone, GJ, Baker, CJ, Impaired chemotaxigenesis by type III group B streptococci in neonatal sera: relationship to diminished concentration of specific anticapsular antibody and abnormalities of serum complement. Pediatr Res 17 (1983), 496–502.
122. Baker, CJ, Paoletti, LC, Rench, MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 182 (2000), 1129–1138.
123. Kasper, DL, Paoletti, LC, Wessels, MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 98 (1996), 2308–2314.
124. Baker, CJ, Paoletti, LC, Rench, MA, Guttormsen, HK, Edwards, MS, Kasper, DL, Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 189 (2004), 1103–1112.
125. Baker, CJ, Rench, MA, Fernandez, M, Paoletti, LC, Kasper, DL, Edwards, MS, Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 188 (2003), 66–73.
126. Madhi, SA, Cutland, CL, Jose, L, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis 16 (2016), 923–934.
127. Donders, GG, Halperin, SA, Devlieger, R, et al. Maternal immunization with an investigational trivalent group B streptococcal vaccine: a randomized controlled trial. Obstet Gynecol 127 (2016), 213–221.
128. Heyderman, RS, Madhi, SA, French, N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis 16 (2016), 546–555.
129. Paoletti, LC, Rench, MA, Kasper, DL, Molrine, D, Ambrosino, D, Baker, CJ, Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 69 (2001), 6696–6701.
130. Hillier S, Ferris D, Fine D, Ferrieri P, Edwards M, Carey V. Women receiving group B streptococcus serotype III tetanus toxoid (GBS III–TT) vaccine have reduced vaginal and rectal acquisition of GBS type III. Annual meeting of the Infectious Diseases Society of America; Philadelphia, PA; Oct 29–Nov 1, 2009. 186.
131. Baker, CJ, Rench, MA, McInnes, P, Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21 (2003), 3468–3472.
132. Bellais, S, Six, A, Fouet, A, et al. Capsular switching in group B streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development. J Infect Dis 206 (2012), 1745–1752.
133. Tien, N, Ho, CM, Lin, HJ, et al. Multilocus sequence typing of invasive group B streptococcus in central area of Taiwan. J Microbiol Immunol Infect 44 (2011), 430–434.
134. Meehan, M, Cunney, R, Cafferkey, M, Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching. Eur J Clin Microbiol Infect Dis 33 (2014), 1155–1162.
135. Openshaw, PJ, Chiu, C, Culley, FJ, Johansson, C, Protective and harmful immunity to RSV infection. Annu Rev Immunol, 2017, 10.1146/annurev-immunol-051116-052206 published online Feb 6.
136. Guvenel, AK, Chiu, C, Openshaw, PJ, Current concepts and progress in RSV vaccine development. Expert Rev Vaccines 13 (2014), 333–344.
137. Munoz, FM, Piedra, PA, Glezen, WP, Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 (2003), 3465–3467.
138. Eberhardt, CS, Blanchard-Rohner, G, Lemaître, B, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62 (2016), 829–836.
139. Madhi, SA, Dangor, Z, Heath, PT, et al. Considerations for a phase-III trial to evaluate a group B streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 31:suppl 4 (2013), D52–D57.
140. Salisbury, D, Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 37 (2001), S34–S36.
141. Roberts, JN, Gruber, MF, Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine 33 (2015), 966–972.
142. Kinyanjui, TM, House, TA, Kiti, MC, Cane, PA, Nokes, DJ, Medley, GF, Vaccine induced herd immunity for control of respiratory syncytial virus disease in a low-income country setting. PLoS One, 10, 2015, e0138018.
143. Ladhani, SN, Andrews, NJ, Southern, J, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin Infect Dis 61 (2015), 1637–1644.
144. Gans, H, Yasukawa, L, Rinki, M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184 (2001), 817–826.
145. Siegrist, CA, Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21 (2003), 3406–3412.
146. Edwards, KM, Maternal antibodies and infant immune responses to vaccines. Vaccine 33 (2015), 6469–6472.
147. Murphy, BR, Alling, DW, Snyder, MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 24 (1986), 894–898.
148. Yamazaki, H, Tsutsumi, H, Matsuda, K, Nagai, K, Ogra, PL, Chiba, S, Effect of maternal antibody on IgA antibody response in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. J Gen Virol 75 (1994), 2115–2119.
149. Shinoff, JJ, O'Brien, KL, Thumar, B, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 198 (2008), 1007–1015.
150. Taylor, G, Bovine model of respiratory syncytial virus infection. Curr Top Microbiol Immunol 372 (2013), 327–345.
151. Taylor, G, Thom, M, Capone, S, et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med, 7, 2015, 300ra127.
152. Vangeel, I, Antonis, AF, Fluess, M, Riegler, L, Peters, AR, Harmeyer, SS, Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV. Vet J 174 (2007), 627–635.
153. Kimman, TG, Westenbrink, F, Schreuder, BE, Straver, PJ, Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies. J Clin Microbiol 25 (1987), 1097–1106.
154. Uttenthal, A, Larsen, LE, Philipsen, JS, et al. Antibody dynamics in BRSV-infected Danish dairy herds as determined by isotype-specific immunoglobulins. Vet Microbiol 76 (2000), 329–341.
155. van der Sluijs, MT, Kuhn, EM, Makoschey, B, A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody. BMC Vet Res, 6, 2010, 2.
156. Hagglund, S, Hu, KF, Larsen, LE, et al. Bovine respiratory syncytial virus ISCOMs—protection in the presence of maternal antibodies. Vaccine 23 (2004), 646–655.
157. Jones, BG, Sealy, RE, Surman, SL, et al. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine 32 (2014), 3264–3273.
158. Prince, GA, Potash, L, Horswood, RL, et al. Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 23 (1979), 723–728.
159. Noh, Y, Shim, BS, Cheon, IS, et al. Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice. Viral Immunol 26 (2013), 268–276.
160. Siegrist, CA, Plotnicky-Gilquin, H, Cordova, M, et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J Infect Dis 179 (1999), 1326–1333.
161. Brandt, C, Power, UF, Plotnicky-Gilquin, H, et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 176 (1997), 884–891.
162. Okamoto, Y, Tsutsumi, H, Kumar, NS, Ogra, PL, Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization. J Immunol 142 (1989), 2507–2512.
163. Kimman, TG, Westenbrink, F, Straver, PJ, Priming for local and systemic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus, virus replication, route of administration and maternal antibodies. Vet Immunol Immunopathol 22 (1989), 145–160.
164. Sandbulte, MR, Roth, JA, T-cell populations responsive to bovine respiratory syncytial virus in seronegative calves. Vet Immunol Immunopathol 84 (2002), 111–123.
165. Bangham, CR, Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology 59 (1986), 37–41.
166. Daly, KA, Scott Giebink, G, Lindgren, BR, et al. Maternal immunization with pneumococcal 9-valent conjugate vaccine and early infant otitis media. Vaccine 32 (2014), 6948–6955.
167. Blanchard-Rohner, G, Snape, MD, Kelly, DF, et al. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. Pediatr Infect Dis J 32 (2013), 768–776.
168. Oster, G, Edelsberg, J, Hennegan, K, et al. Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?. Vaccine 32 (2014), 4778–4785.
169. Kim, SY, Russell, LB, Park, J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine 32 (2014), 1954–1963.
170. Régnier, SA, Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine 31 (2013), 4347–4354.
171. Meijboom, MJ, Rozenbaum, MH, Benedictus, A, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine 30 (2012), 4691–4700.
172. Pouwels, KB, Bozdemir, SE, Yegenoglu, S, et al. Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: an illustration based on bursa data. PLoS One, 11, 2016, e0163567.